Bristol-Myers Squibb (BMY)

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Bristol Myers Squibb just agreed to shower BioNTech with cash.

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high dividend yield, strong profitability, and an undervalued stock price, making it a candidate for value investors.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers a high 5.29% dividend yield with strong growth and profitability, making it a solid pick for income investors.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.

It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.